Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines

Casein kinase II (CK2) and cyclin-dependent kinases (CDKs) frequently interact within multiple pathways in pancreatic ductal adenocarcinoma (PDAC). Application of CK2- and CDK-inhibitors have been considered as a therapeutic option, but are currently not part of routine chemotherapy regimens. We inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yixuan, Sender, Sina, Sekora, Anett, Kong, Weibo, Bauer, Peter, Ameziane, Najim, Krake, Susann, Radefeldt, Mandy, Al-Ali, Ruslan, Weiss, Frank Ulrich, Lerch, Markus M., Parveen, Alisha, Zechner, Dietmar, Junghanss, Christian, Murua Escobar, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031017/
https://www.ncbi.nlm.nih.gov/pubmed/35457227
http://dx.doi.org/10.3390/ijms23084409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031017/
https://www.ncbi.nlm.nih.gov/pubmed/35457227
http://dx.doi.org/10.3390/ijms23084409

Ejemplares similares